# Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

> **NCT00983060** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Chronic Hepatitis C Genotype-1 Relapse

## Interventions

- **DRUG:** NIM811
- **DRUG:** Placebo BID + SOC

## Key facts

- **NCT ID:** NCT00983060
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983060, "Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00983060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*